Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 178.03M | $ 60.28M | $ 27.15M | $ 6.15M | $ 3.96M |
| Gross Profit | $ 177.96M | $ 50.42M | $ -100.58M | $ -104.94M | $ -87.61M |
| Operating Income | $ -68.76M | $ -138.04M | $ -163.97M | $ -162.25M | $ -133.41M |
| EBITDA | $ -52.66M | $ -128.20M | $ -155.59M | $ -155.68M | $ -125.81M |
| Net Income | $ -70.81M | $ -113.87M | $ -165.46M | $ -158.09M | $ -130.09M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 151.60M | $ 146.94M | $ 204.60M | $ 369.58M | $ 368.22M |
| Total Assets | $ 245.96M | $ 282.62M | $ 328.92M | $ 469.55M | $ 451.14M |
| Total Debt | $ 74.21M | $ 25.23M | $ 23.08M | $ 25.47M | $ 23.71M |
| Net Debt | $ -16.93M | $ -118.76M | $ -84.96M | $ -124.48M | $ -33.17M |
| Total Liabilities | $ 234.11M | $ 243.10M | $ 247.04M | $ 263.58M | $ 109.92M |
| Stockholders' Equity | $ 11.85M | $ 39.51M | $ 81.88M | $ 205.96M | $ 341.23M |
| Cash Flow | |||||
| Free Cash Flow | $ -75.93M | $ -145.76M | $ -171.51M | $ 1.95M | $ -56.50M |
| Operating Cash Flow | $ -73.21M | $ -140.88M | $ -141.77M | $ 10.73M | $ -53.59M |
| Investing Cash Flow | $ -58.95M | $ 176.54M | $ 89.14M | $ 75.80M | $ -278.92M |
| Financing Cash Flow | $ 78.75M | $ 880.00K | $ 12.87M | $ 3.29M | $ 340.05M |